Efficacy And Predictive Markers Of Response To Tofacitinib And Baricitinib Therapy In Alopecia Areata: A 52-Week Comparative Cohort Study

April 2026 in “ Meditsinskiy sovet = Medical Council ”

N. N. Potekaev, A.G. Gadzhigoroeva, G. P. Tereshchenko, El Hawi Chaza, O. Zhukova

tofacitinib baricitinib alopecia areata SALT30 SALT ≤20% hair regrowth

TLDR Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

The study compares the efficacy and predictive markers of response to tofacitinib and baricitinib therapy in patients with alopecia areata over a 52-week period. It highlights that both treatments are effective, but individual responses can vary based on specific predictive markers. The study emphasizes the importance of identifying these markers to tailor treatments for better outcomes. The research provides valuable insights into optimizing therapeutic strategies for alopecia areata, although the document does not specify the number of participants involved in the study.

View this study on med-sovet.pro →

Discuss this study in the Community →

Research cited in this study

25 / 25 results

research Jak Inhibitors in the Treatment of Alopecia Areata: A Literature Review

June 2025 in “Journal of Education Health and Sport”

Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.

research Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data

4 citations , May 2025 in “Frontiers in Immunology”

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme

13 citations , February 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center

research Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center

January 2025 in “The Journal of Dermatology”

Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.

research Real-Life Effectiveness and Safety of Baricitinib in 17 Japanese Patients With Alopecia Areata: A 60-Week Single Center Study

January 2025 in “Journal of Cutaneous Immunology and Allergy”

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

research Baricitinib Achieved Complete or Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials

January 2025 in “SKIN The Journal of Cutaneous Medicine”

Baricitinib significantly regrows hair in severe alopecia areata patients.

research Predictors And Management Of Inadequate Response To JAK Inhibitors In Alopecia Areata

11 citations , September 2024 in “American Journal of Clinical Dermatology”

Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.

research Alopecia Areata of the Nails: Diagnosis and Management

2 citations , June 2024 in “Journal of Clinical Medicine”

Alopecia Areata can affect nails, often improving on its own, but JAK inhibitors may help.

Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel

research Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel

April 2024 in “Frontiers in medicine”

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients

January 2024 in “Acta dermato-venereologica”

Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study

research Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-Centre Real-World Retrospective Study

December 2023 in “Acta dermato-venereologica”

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

research Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study

2 citations , November 2023 in “Acta dermato-venereologica”

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

research Alopecia Areata: Current Treatments and New Directions

57 citations , August 2023 in “American Journal of Clinical Dermatology”

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

1 citations , August 2023 in “JAMA Dermatology”

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

research Janus Kinase Inhibitors for Alopecia Areata

7 citations , August 2023 in “Journal of the American Academy of Dermatology”

JAK inhibitors offer new hope for treating severe alopecia areata.

research Baricitinib for the Treatment of Alopecia Areata

6 citations , May 2023 in “Drugs”

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

research Alopecia Areata: An Updated Review for 2023

91 citations , May 2023 in “Journal of Cutaneous Medicine and Surgery”

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response

April 2023 in “Journal of the American Academy of Dermatology”

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

research A Retrospective Study of Oral Tofacitinib Therapy for Alopecia Areata

2 citations , January 2023 in “Anais Brasileiros de Dermatologia”

$Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population$

research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population

2 citations , September 2022 in “Dermatologic Therapy”

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

research Alopecia Areata and Tofacitinib: A Prospective Multicenter Study from a Saudi Population

9 citations , October 2021 in “International Journal of Dermatology”

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

research The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials

86 citations , January 2020 in “British Journal of Dermatology”

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.